Kodiak Sciences drug shows superior results in diabetic retinopathy trial

March 26, 2026 6:01 AM

Kodiak Sciences Inc. (NASDAQ: KOD) announced positive results from its GLOW2 Phase 3 study, showing its experimental drug Zenkuda demonstrated ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found